ArticleScientific reports2017
FAM19A5, a brain-specific chemokine, inhibits RANKL-induced osteoclast formation through formyl peptide receptor 2.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 39 citations in OpenAlex.
- Proteomic alterations in patient bone-derived stromal cells and their secretomes in osteogenesis imperfecta.Molecular genetics and metabolism reports · 2026Article
- Chromosome 22q13 terminal deletion size is associated with relevant clinical features in a sample of 63 Italian patients with Phelan-McDermid syndrome.Journal of neurodevelopmental disorders · 2026Article
- GWAS-based polygenic profiling across broad sport categories: shared and category-specific genetic associations with athlete status and polygenic differences from population controls.Frontiers in sports and active living · 2026Article
- Identification of anti-resorptive GPCRs by high-content imaging in human osteoclasts.Journal of molecular endocrinology · 2025Article
- The origin, evolution, and molecular diversity of the chemokine system.Life science alliance · 2024Article
- Can Adipokine FAM19A5 Be a Biomarker of Metabolic Disorders?Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Review
- Formyl peptide receptors in bone research.Connective tissue research · 2023Review
- Molecular Structure, Expression and Role of TAFA4 and its Receptor FPR1 in the Spinal Cord.Frontiers in cell and developmental biology · 2022Review
- FAM19A5l Affects Mustard Oil-Induced Peripheral Nociception in Zebrafish.Molecular neurobiology · 2021Article
- Circulating levels of FAM19A5 are inversely associated with subclinical atherosclerosis in non-alcoholic fatty liver disease.BMC endocrine disorders · 2021Article
- Isovaleric acid ameliorates ovariectomy-induced osteoporosis by inhibiting osteoclast differentiation.Journal of cellular and molecular medicine · 2021Article
- FAM19A (TAFA): An Emerging Family of Neurokines with Diverse Functions in the Central and Peripheral Nervous System.ACS chemical neuroscience · 2021Review
- The effect of the WKYMVm peptide on promoting mBMSC secretion of exosomes to induce M2 macrophage polarization through the FPR2 pathway.Journal of orthopaedic surgery and research · 2021Article
- Sphingosylphosphorylcholine blocks ovariectomy-induced bone loss by suppressing CaJournal of cellular and molecular medicine · 2021Article
- Deorphanizing FAM19A proteins as pan-neurexin ligands with an unusual biosynthetic binding mechanism.The Journal of cell biology · 2020Article
- The protective effect of WKYMVm peptide on inflammatory osteolysis through regulating NF-κB and CD9/gp130/STAT3 signalling pathway.Journal of cellular and molecular medicine · 2020Article
- Association of Serum FAM19A5 with Cognitive Impairment in Vascular Dementia.Disease markers · 2020Article
- Adipokines: New Potential Therapeutic Target for Obesity and Metabolic, Rheumatic, and Cardiovascular Diseases.Frontiers in physiology · 2020Review
- FAM19A1, a brain-enriched and metabolically responsive neurokine, regulates food intake patterns and mouse behaviors.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
- TAFA5 promotes proliferation and migration in gastric cancer.Molecular medicine reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoclasts can be differentiated from bone marrow-derived macrophages (BMDM). They play a key role in bone resorption. Identifying novel molecules that can regulate osteoclastogenesis has been an important issue. In this study, we found that FAM19A5, a neurokine or brain-specific chemokine, strongly stimulated mouse BMDM, resulting in chemotactic migration and inhibition of RANKL-induced osteoclastogenesis. Expression levels of osteoclast-related genes such as RANK, TRAF6, OSCAR, TRAP, Blimp1, c-fos, and NFATc1 were markedly decreased by FAM19A5. However, negative regulators of osteoclastogenesis such as MafB and IRF-8 were upregulated by FAM19A5. FAM19A5 also downregulated expression levels of RANKL-induced fusogenic genes such as OC-STAMP, DC-STAMP, and Atp6v0d2. FAM19A5-induced inhibitory effect on osteoclastogenesis was significantly reversed by a formyl peptide receptor (FPR) 2 antagonist WRW4 or by FPR2-deficiency, suggesting a crucial role of FPR2 in the regulation of osteoclastogenesis. Collectively, our results suggest that FAM19A5 and its target receptor FPR2 can act as novel endogenous ligand/receptor to negatively regulate osteoclastogenesis. They might be regarded as potential targets to control osteoclast formation and bone disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.